Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Increase in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 177,544 shares, a growth of 571.2% from the July 15th total of 26,452 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 466,302 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds have recently added to or reduced their stakes in ENLV. Jane Street Group LLC boosted its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the 3rd quarter valued at about $57,000. Renaissance Technologies LLC lifted its position in Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares during the last quarter. HRT Financial LP lifted its position in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after buying an additional 19,132 shares in the last quarter. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Stock Performance

NASDAQ ENLV opened at $1.69 on Friday. Enlivex Therapeutics has a 52-week low of $1.68 and a 52-week high of $31.50. The company has a market capitalization of $28.44 million, a P/E ratio of -0.20 and a beta of 1.60. The company has a fifty day moving average of $6.27 and a 200-day moving average of $11.58.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ENLV. Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.